Dietrich John Pauls - 01 Jun 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: President and CEO, Director
Signature: /s/ Amy Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 01 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Jun 2022, 17:06:36 UTC
Previous filing: 16 Aug 2021
Next filing: 16 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						35,804	01 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+177,000		$0.000000	177,000	01 Jun 2022	Common Shares	177,000	$2.45	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
F2	Vests with respect to 25% of the underlying common shares on June 1, 2023 and with respect to the remaining 75% of the underlying common shares in 36 as nearly equal as possible monthly installments commencing on July 1, 2023.